Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2020 Edition) / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 78-91, 2021.
Artigo
em Chinês
| WPRIM
| ID: wpr-877499
ABSTRACT
Antibody-drug conjugate (ADC) is a type of targeted biological agent which connect cytotoxic drug to monoclonal antibody by a connector head, which enables monoclonal antibody acted as a carrier to efficiently transport small molecular cytotoxic drugs to target tumor cells. It is very important for clinicians to have an in-depth understanding of the molecular characteristics and mechanism of ADC drugs, rationally choose the appropriate dose, course of treatment and manage adverse reactions according to the indications during the clinical application of ADC drugs, which may even affect the survival of patients. Therefore, the consensus aims to conduct a systematic overview of commercially available ADC drugs, provide effective recommendations and references for clinicians to better apply and manage ADC drugs.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Imunoconjugados
/
Consenso
/
Anticorpos Monoclonais
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Guia de Prática Clínica
/
Revisões Sistemáticas Avaliadas
Limite:
Humanos
Idioma:
Chinês
Revista:
Chinese Journal of Oncology
Ano de publicação:
2021
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS